Small Molecules

23 April 2013

Pre-clinical results on naproxcinod in models of muscular dystrophy presented at MDA Scientific Conference

23 April 2013

Galapagos starts Phase 2A study with GLPG0974 in ulcerative colitis

23 April 2013

Novartis once-daily QVA149 shows superior efficacy in reducing exacerbations, improving lung function and quality of life in COPD patients

23 April 2013

Data from Phase 3 Studies of Gilead’s Sofosbuvir for Hepatitis C

23 April 2013

High Rates of SVR Demonstrated in Phase II Study with Investigational Triple DAA Regimen of Daclatasvir, Asunaprevir and BMS-791325 in Treatment-Naïve Patients with Genotype 1 Chronic Hepatitis C Infection

23 April 2013

Enanta Announces New Data From Phase 2b Interferon-Free Combination Studies with Protease Inhibitor ABT-450 for Hepatitis C Treatment to be Presented at EASL

23 April 2013

FDA Approves Supplemental New Drug Application for AMITIZA® (lubiprostone), the First Oral Treatment for Opioid-induced Constipation in Adults with Chronic Non-Cancer Pain

23 April 2013

Convergence Pharmaceuticals Announces Start of Phase II Study for Cav2.2 Selective Blocker, CNV2197944 in Pain Associated with Post-Herpetic Neuralgia

23 April 2013

ALS-2200 (VX-135) Viral Kinetic Study Shows Significant Reduction in HCV RNA in People with Genotype 1 Hepatitis C Virus Infection and Cirrhosis, and in People with Genotypes 2, 3 or 4 HCV Infection

22 April 2013

Synta Announces First Patients Treated in Pivotal GALAXY-2 Trial Evaluating Ganetespib in Advanced Non-Small Cell Lung Cancer

22 April 2013

Safinamide Phase III study resultspresented at 2013 MDPD meeting

21 April 2013

ADial Pharmaceuticals Announces Agreement With FDA For Phase III Trial Of AD04 For Alcohol Use Disorder In Patients Of Targeted Genotypes

21 April 2013

Pharmacyclics Completes Enrollment of First Phase III Ibrutinib CLL Study – RESONATE™ and Announces Completion of Enrollment of Phase II Ibrutinib MCL Study – SPARK

21 April 2013

Alcon announces FDA approval of Simbrinza(TM) Suspension, a new beta blocker-free, fixed-combination therapy for glaucoma patients

20 April 2013

Civitas Therapeutics Announces Positive Phase 2 Clinical Results for CVT-301, an Inhaled L-dopa for Parkinson’s Disease

20 April 2013

Grunenthal Highlights Significant R&D Advances in Pain, Inflammation as well as INTAC Tamper-Resistant Technology at World’s Largest Biotechnology Conference

20 April 2013

Treatment with VX-661 and Ivacaftor in a Phase 2 Study Resulted in Statistically Significant Improvements in Lung Function in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation

18 April 2013

Savara Pharmaceuticals Initiates Phase 2 Clinical Trial of AeroVanc for MRSA Lung Infection in Cystic Fibrosis Patients

18 April 2013

Romark Laboratories Initiates Phase 3 Trial of New Influenza Drug

18 April 2013

Targacept Completes Recruitment in Phase 2b Schizophrenia Trial of TC-5619

18 April 2013

Debiopharm Group to Support Ascepion in the Development of Debio 1144 for the Treatment of Chinese Cancer Patients

18 April 2013

Resverlogix Completes Dosing In ASSURE Clinical Trial

18 April 2013

Addex Dipraglurant Normalizes Striatal Cholinergic Dysfunction in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1 (DYT1)

18 April 2013

SK Biopharmaceuticals Announces U.S. FDA’s Authorization of IND for SKL15508

18 April 2013

FDA Advisory Committee recommends approval of BREO(TM) ELLIPTA(TM) for the treatment of COPD

17 April 2013

BioLineRx Announces Positive Phase II Results for BL-7040, an Orally Available Treatment for Inflammatory Bowel Disease

17 April 2013

Alkermes Announces Positive Results from Phase 2 Clinical Study of ALKS 5461 for Major Depressive Disorder

17 April 2013

Stem Cell Therapeutics Licenses Exclusive Rights to Clinical Cancer Stem Cell Program

17 April 2013

First Patient Enrolled in Global Phase III Program Evaluating Bayer’s Amikacin Inhale in Intubated and Mechanically Ventilated Patients with Gram-negative Pneumonia

17 April 2013

BioAlliance Pharma’s Sitavig Receives Market Authorization in the US For the Treatment of Herpes Labialis

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

CCR8-Targeted Antibody Immunotherapy Pipeline Review

Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Fibroblast Activation Protein (FAP) Targeted Therapy & Companion Diagnostic Pipeline Review

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

PD-1 x VEGF and PD-L1 x VEGF bispecific antibodies: a business, pipeline and competitor analysis from an industry perspective